Evaluation and Treatment of a Patient with Recurrent Stroke in the Setting of Active Malignancy
Stroke 50:e9-e11, Neilson, L.E.,et al, 2019
Ischemic Stroke in Cancer Patients: A Review of an Underappreciated Pathology
Ann Neurol 83:873-883, Navi, B.B. & Iadecola, C., 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Anticoagulant and Antiplatelet Use in Seniors with Chronic Subdural Hematoma
Neurol 88:1889-1893, Nathan, S.,et al, 2017
Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 48:2031-2033, Tsivgoulis, G. & Safouris, A., 2017
Long-Term Antithrombotic Treatment in Intracranial Hemorrhage Survivors with Atrial Fibrillation
Neurol 89:687-696, Korompoki, E.,et al, 2017
Three Territory DWI Acute Infarcts: Diagnostic Value in Cancer-Associated Hypercoagulation Stroke (Trousseau Syndrome)
AJNR 37: Nov, Finelli, P.F. & Nouh, A., 2016
Early Start of DOAC after Ischemic Stroke
Neurol 87:1856-1862,1652, Seiffge, D.J.,et al, 2016
Recurrence of ICH after Resumption of Anticoagulation with VK Antagonists
Neurol 82:1020-1026,1016, Poli, D.,et al, 2014
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
New Antithrombotic Drugs for Atrial Fibrillation: Caution is Needed
Lancet 379:e24, Bell,S.,et al, 2012
Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012
Intracraial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation with Warfarin or Dabigatran
Stroke 43:1511-1517, Hart, R.G.,et al, 2012
Spinal Haemorrhage During Anticoagulant Regimen for Thromboprophylaxis: A Unique Form of Central Nervous System Haemorrhage
JNNP 83:746-752, Furlan, J.C.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Cerebral Venous Sinus Thrombosis Associated with Cerebral Hemorrhage Is Anticoagulant Treatment Safe?
The Neurologist 17:208-210, Fuentes, B.,et al, 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy: The Bleeding With Antithrombotic Therapy (BAT) Study
Stroke 41:1440-1444, Toyoda,K., et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians
Stroke 39:227-230,7, Gattellari,M.,et al, 2008
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008
Association Between Cerebral Microbleeds on T2*-Weighted MR Images and Recurrent Hemorrhagic Stroke in Patients Treated With Warfarin Following Ischemic Stroke
AJNR 29:1483-1486, Ueno,H.,et al., 2008
Cerebral Venous Thrombosis: A Descriptive Multicenter Study of Patients in Pakistan and Middle East
Stroke 39:2707-2711, Khealani,B.,et al, 2008
Admission International Normalized Ratio and Acute Infarct Volume in Ischemic Stroke
Ann Neurol 64:499-506, Ay,H.,et al, 2008
The Increasing Incidence of Anticoagulant-Associated Intracerebral Hemorrhage
Neurol 68:116-121, Flaherty,M.L.,et al, 2007
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials
Stroke 38:423-430, Paciaroni,M.,et al, 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?
Stroke 38:1652-1654, Gorelick,P.B., 2007
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
NEJM 352:1305-1316, 1368, Chimowitz,M.I.,et al, 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Cerebral Venous Thrombosis: Influence of Risk Factors and Imaging Findings on Prognosis
Clin Neurol Neurosurg 107:371-378, Appenzeller,S.,et al, 2005
Antithrombotic Drugs for Carotid Artery Dissection
Stroke 25:613-614, Lyrer,P.&Engelter,S., 2004
Combined Anticoagulant-Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation Patients
Stroke 35:2362-2367, Shireman,T.I.,et al, 2004
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 34:1056-1083, Adams,H.P.,et al, 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Intracerebral Hemorrhages Associated with Neurointerventional Procedures Using a Combination of Antithrombotic Agents Including Abciximab
Stroke 33:1916-1919, Qureshi,A.I.,et al, 2002
Systematic Review of Long Term Anticoagulation or Antiplatelet Treatment in Patients with Non-rheumatic Atrial Fibrillation
BMJ 322:321-326, Taylor,F.C.,et al, 2001
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Safety of Anticoagulation for Cerebral Venous Thrombosis Associated with Intracerebral Hematoma
Neurol 57:1138-1139, Fink,J.N.&McAuley,D.L., 2001
Oral Anticoagulation for Cerebral Ischemic of Arterial Origin
Neurol 57:1993-1999, Torn,M.,et al, 2001
Cerebral Sinus Thrombosis Diagnosed by MRI and MR Venography in Cancer Patients
Neurol 54:1222-1226, Raizer,J.J.&DeAngelis,L.M., 2000